Post Type Archives: Blog

Eli Lilly’s rheumatoid arthritis medication, Olumiant (baricitinib), is currently in phase 3 clinical trials to become a potential drug used in the treatment of COVID-19. This discovery was made possible by artificial intelligence analysis by BenevolentAI. BenevolentAI used machine learning to read through scientific literature to search for an approved drug that has the capability […]

According to the Centers for Disease Control and Prevention (CDC), elderly patients are at increased risk of complications and death from the COVID-19 virus than the rest of the population. In the United States, 8 out of 10 deaths reported were in people 65 years of age and older. Older adults have increased risks associated […]

Human longevity. Long have men sought to predict or control their own lifespans or improve their vitalities. Many cultures have invented remedies to cure various illnesses or to repel the embrace of Death which inevitably finds us all. In the 17th century, King Charles II took to a combination of alcohol with powdered skull bones […]

A breakthrough has been discovered in one of the world’s biggest randomized, controlled trials for coronavirus treatment. Based in the United Kingdom, the RECOVERY trial enrolled a total of 2,100 participants who received an inexpensive and commonly used steroid, dexamethasone. The participants were compared to 4,300 people who received standard care. The cohorts showing the […]

Tauvid (flortaucipir F18) was recently approved for intravenous injection during PET imaging of for patients being evaluated for Alzheimer’s disease after being granted Priority Review by the FDA. Tauvid is a radioactive diagnostic agent indicated for use during PET imaging to estimate the density and distribution of tau-associated neurofibrillary tangles (NFTs), which is a primary […]

An intriguing new study was published this month in The Journal of the American Geriatrics Society, proposing that personality traits may be a valuable predictor for the risk of developing pre-dementia syndromes.    The impact of personality traits have been observed previously by researchers who linked traits such as neuroticism and conscientiousness to dementia and […]

On June 4th, 2020 the FDA approved Recarbrio (imipenem-cilastatin and relebactam) to treat HAP/VAP in patients over 18 years old. This drug includes imipenem, which binds to PBP 2 and  PBP 1B on certain bacteria therefore inhibiting PBP leading to the disruption of bacterial cell wall synthesis, and cilastatin which is a renal dehydropeptidase inhibitor […]

The FDA has officially authorized the first at-home sample collection kit that can be sent off to two different laboratories for COVID-19 diagnostic testing. Everlywell, Inc. was issued an emergency use authorization (EUA) from the FDA for its at-home COVID-19 sample collection kit. The kit is authorized to be used by individuals in the comfort […]